

## 187 Digitalis Glycosides

### REFERENCES

1. Haynes K, Heitjan D, Kanetsky P, Hennessy S: Declining public health burden of digoxin toxicity from 1991 to 2004. *Clin Pharmacol Ther* 84: 90, 2008.
2. Smith TW: Digitalis. Mechanisms of action and clinical use. *N Engl J Med* 318: 358, 1988.
3. Gheorghiade M, van Veldhuisen DJ, Colucci WS: Contemporary use of digoxin in the management of cardiovascular disorders. *Circulation* 113: 2556, 2006.
4. Rosen MR: Cellular electrophysiology of digitalis toxicity. *J Am Coll Cardiol* 5: 22A, 1985.
5. Piltz JR, Wertenbaker C, Lance SE, et al: Digoxin toxicity. Recognizing the varied visual presentations. *J Clin Neuroophthalmol* 13: 275, 1993.
6. Ma G, Brady WJ, Pollack M, Chan TC: Electrocardiographic manifestations: digitalis toxicity. *J Emerg Med* 20: 145, 2001.
7. Moorman JR, Pritchett EL: The arrhythmias of digitalis intoxication. *Arch Intern Med* 145: 1289, 1985.
8. Bismuth C, Gaultier M, Conso F, Efthymiou ML: Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. *Clin Toxicol* 6: 153, 1973.
9. Wofford JL, Ettinger WH: Risk factors and manifestations of digoxin toxicity in the elderly. *Am J Emerg Med* 9: 11; discussion 33, 1991.
10. Juurlink DN, Mamdani M, Kopp A, et al: Drug-drug interactions among elderly patients hospitalized for drug toxicity. *JAMA* 289: 1652, 2003.
11. Vivo RP, Krim SR, Perez J, et al: Digoxin: current use and approach to toxicity. *Am J Med Sci* 336: 423, 2008.
12. Schmiedl S, Szymanski J, Rottenkolber M, et al: Re: Age- and gender-specific incidence of hospitalisation for digoxin intoxication. *Drug Saf* 30: 1171; author reply 1173, 2007.
13. Menduiña MJ, Candel JM, Alaminos P, et al: Bidirectional ventricular tachycardia due to digitalis poisoning. *Rev Esp Cardiol* 58: 991, 2005.
14. Selzer A: Role of serum digoxin assay in patient management. *J Am Coll Cardiol* 5: 106A, 1985.
15. Dasgupta A, Emerson L: Neutralization of cardiac toxins oleandrin, oleandrenin, bufalin, and cinobufotalin by Digibind: monitoring the effect by measuring free digitoxin concentrations. *Life Sci* 63: 781, 1998.
16. French JH, Thomas RG, Siskind AP, et al: Magnesium therapy in massive digoxin intoxication. *Ann Emerg Med* 13:562, 1984.
17. Chen JY, Liu PY, Chen JH, Lin LJ: Safety of transvenous temporary cardiac pacing in patients with accidental digoxin overdose and symptomatic bradycardia. *Cardiology* 102: 152, 2004.
18. Antman EM, Wenger TL, Butler VP Jr, et al: Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. *Circulation* 81: 1744, 1990.
19. Roberts DM, Buckley NA: Antidotes for acute cardenolide (cardiac glycoside) poisoning. *Cochrane Database Syst Rev* 4: CD005490, 2006.
20. Lapostolle F, Borron SW, Verdier C, et al: Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. *Crit Care Med* 36: 3014, 2008.
21. Hack JB, Woody JH, Lewis DE, et al: The effect of calcium chloride in treating hyperkalemia due to acute digoxin toxicity in a porcine model. *J Toxicol Clin Toxicol* 42: 337, 2004.
22. Van Deusen SK, Birkhahn RH, Gaeta TJ: Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity. *J Toxicol Clin Toxicol* 41: 373, 2003.
23. Levine M, Nikkanen H, Pallin DJ: The effects of intravenous calcium in patients with digoxin toxicity. *J Emerg Med*. Epub ahead of print February 5, 2009.
24. Rajapakse S: Management of yellow oleander poisoning. *Clin Toxicol (Phila)* 47: 206, 2009.
25. Ramlakhan SL, Fletcher AK: It could have happened to Van Gogh: a case of fatal purple foxglove poisoning and review of the literature. *Eur J Emerg Med* 14: 356, 2007.
26. Hickey AR, Wenger TL, Carpenter VP, et al: Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. *J Am Coll Cardiol* 17: 590, 1991.
27. Kirkpatrick CH: Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. The Digibind Study Advisory Panel. *Am J Emerg Med* 9: 7; discussion 33, 1991.
28. Clifton GD, McIntyre WJ, Zannikos PN, et al: Free and total serum digoxin concentrations in a renal failure patient after treatment with digoxin immune Fab. *Clin Pharm* 8: 441, 1989.
29. Ujhelyi MR, Robert S: Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. *Clin Pharmacokinet* 28: 483, 1995.
30. Zdunek M, Mitra A, Mokrzycki MH: Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: timing is important for maximizing clearance. *Am J Kidney Dis* 36: 177, 2000.
31. Bateman DN: Digoxin-specific antibody fragments: how much and when? *Toxicol Rev* 23: 135, 2004.

### USEFUL WEB RESOURCES

The American Association of Poison Control Centers (AAPC)—<http://www.aapcc.org/DNN>  
 The American Academy of Clinical Toxicology (AACT)—<http://www.clintox.org/index.cfm>  
 The European Association of Poisons Centres and Clinical Toxicologists (EAPCCT)—<http://www.eapcct.org>  
 The Asia Pacific Association of Medical Toxicology (APAMT)—<http://www.asiatox.org>  
 The South Asian Clinical Toxicology Research Collaboration (SACTRC)—<http://www.sactrc.org>  
 TOXBASE: The primary clinical toxicology database of the National Poisons Information Service—<http://www.toxbase.org>. (Free access for UK National Health Service hospital departments and general practices, NHS Departments of Public Health and Health Protection Agency Units. Available to hospital emergency departments in Ireland by contract. Available to European Poison Centers whose staff are members of the European Association of Poisons Centres and Clinical Toxicologists. Overseas users may be allowed access on payment of a yearly subscription, subject to approval of the Health Protection Agency.)